Quick Answer
BIO-RAD LABORATORIES, INC. reported Total Revenue of $2.16 billion for fiscal year 2017.
BIO-RAD LABORATORIES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | $759.90M +141.2% |
-$1.84B -189.4% |
-$637.30M +82.4% |
-$3.63B -185.3% |
$4.25B +11.5% |
$3.81B +116.9% |
| Diluted EPS | $27.85 +142.6% |
-$65.36 -199.5% |
-$21.82 +82.1% |
-$121.79 -186.5% |
$140.83 +11.4% |
$126.47 +117.0% |
| Total Assets | $10.58B +12.9% |
$9.36B -23.9% |
$12.30B -8.9% |
$13.50B -24.1% |
$17.80B +37.2% |
$12.97B +62.0% |
| Cash and Equivalents | $529.80M +8.5% |
$488.10M +20.9% |
$403.80M -7.0% |
$434.20M -7.8% |
$470.78M -28.9% |
$662.21M +0.2% |
| Long-Term Debt | $1.20B +0.1% |
$1.20B | — | — | — | — |
| Stockholders Equity | $7.45B +13.5% |
$6.57B -24.8% |
$8.74B -9.1% |
$9.62B -29.7% |
$13.69B +38.4% |
$9.89B +71.8% |
| R&D Expense | $275.60M -6.9% |
$295.90M +19.6% |
$247.40M -3.7% |
$256.90M -1.4% |
$260.64M +19.7% |
$217.76M +7.4% |
| Operating Income | $47.20M -82.5% |
$269.00M -20.4% |
$337.80M -30.0% |
$482.60M -3.5% |
$500.34M +18.8% |
$421.33M +83.5% |
| Gross Profit | $1.34B -2.8% |
$1.38B -3.4% |
$1.43B -9.0% |
$1.57B -4.3% |
$1.64B +13.9% |
$1.44B +14.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $653.00M | +0.5% | +0.2% |
| Revenue (ASC 606) | September 30, 2025 | $653.00M | +0.5% | +0.2% |
| Net Income | September 30, 2025 | -$341.90M | -152.3% | -207.6% |
| Diluted EPS | September 30, 2025 | -$12.70 | -154.4% | -208.8% |
| Total Assets | September 30, 2025 | $9.70B | -8.6% | -5.1% |
| Cash and Equivalents | September 30, 2025 | $395.80M | -3.6% | +7.2% |
| Long-Term Debt | September 30, 2025 | $1.20B | +0.1% | +0.0% |
| Stockholders Equity | September 30, 2025 | $6.74B | -10.0% | -5.5% |
| R&D Expense | September 30, 2025 | $71.30M | -21.6% | +17.9% |
| Operating Income | September 30, 2025 | $65.30M | +1.2% | -15.3% |
| Gross Profit | September 30, 2025 | $343.40M | -3.5% | -0.6% |
- BIO-RAD LABORATORIES, INC. reported Total Revenue of $2.16 billion for fiscal year 2017.
- BIO-RAD LABORATORIES, INC. showed an increase of +4.4% in Total Revenue compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Net Income of $759.90 million for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed an increase of +141.2% in Net Income compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Diluted EPS of $27.85 per share for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed an increase of +142.6% in Diluted EPS compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Total Assets of $10.58 billion for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed an increase of +12.9% in Total Assets compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Cash and Equivalents of $529.80 million for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed an increase of +8.5% in Cash and Equivalents compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Long-Term Debt of $1.20 billion for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed an increase of +0.1% in Long-Term Debt compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Stockholders Equity of $7.45 billion for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed an increase of +13.5% in Stockholders Equity compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported R&D Expense of $275.60 million for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed a decrease of -6.9% in R&D Expense compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Operating Income of $47.20 million for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed a decrease of -82.5% in Operating Income compared to the prior fiscal year.
- BIO-RAD LABORATORIES, INC. reported Gross Profit of $1.34 billion for fiscal year 2025.
- BIO-RAD LABORATORIES, INC. showed a decrease of -2.8% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: